beaute melasma x glutathione brightening tone up cream ingredients Product details of • • Cream for face, 40 ml volume • Suitable for normal, sensitive, and ageing skin • Provides brightening effect • Store in celimax #glutathione #tone_up #Cream #dream_nature

They act as carriers for specific compounds used in pharmaceutical administration

doi: 10.2147/OTT.S131611

Chemical & Physical Properties Toxicological Information CHEMICAL IDENTIFICATION RTECS NUMBER : MC0556000 CHEMICAL NAME : Glycine, N-(N-L-gamma-glutamyl-L-cysteinyl)- CAS REGISTRY NUMBER : 70-18-8 LAST UPDATED : 199710 DATA ITEMS CITED : 20 MOLECULAR FORMULA : C10-H17-N3-O6-S MOLECULAR WEIGHT : 307.36 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4020 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2238 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1250 mg/kg SEX/DURATION : female 1-22 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumorsA phase I trial